- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05071430
Safety and Efficacy of HB-1 for Panic Disorder
Safety and Efficacy of HB-1 for Panic Disorder: A Multicenter, Randomized, Double Blind, Placebo-Controlled Trial
Study Overview
Detailed Description
This is a multicenter, randomized, double-blind, placebo-controlled trial. All patients with Panic Disorder, with or without specified co-morbidities, who meet all of the inclusion and none of the exclusion criteria will be eligible. Patients and researchers will be blinded to their treatment group.
The study will enroll approximately 80 adult patients who meet the diagnosis of panic disorder.
The patients will be treated for 12 weeks including a 1 week safety follow up visit following the last dose of study drug.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Garden Grove, California, United States, 92845
- Collaborative Neuroscience Research
-
San Jose, California, United States, 95124
- Lumos Psychiatric Services
-
-
Connecticut
-
Hartford, Connecticut, United States, 06106
- Institute of Living
-
-
Florida
-
Jacksonville, Florida, United States, 32256
- CNS Healthcare
-
Orlando, Florida, United States, 32801
- CNS Healthcare
-
-
Illinois
-
Chicago, Illinois, United States, 60640
- Uptown Research Institute
-
-
New Jersey
-
Berlin, New Jersey, United States, 08009
- Hassman Research Institute
-
-
New York
-
Brooklyn, New York, United States, 11235
- SPRI Clinical Trials
-
Staten Island, New York, United States, 10312
- Richmond Behavioral Associates
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- CNS Healthcare
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Male or female aged 18 to 60 years old, inclusive, at the time of informed consent.
- Meets DSM-5 Criteria for Panic Disorder.
- Documented moderate to severe levels of symptoms at baseline (Panic Disorder Severity Scale of 13 or above)
- Medically stable on current medication regimen for at least 3 months (including PRN medications), as determined by Investigator.
- Willing to remain on current doses of other psychiatric medications throughout the length of the trial (unless a dose reduction is warranted due to improvement in symptoms).
- Willing and able to safely stop any of the following medications prior to study trial: Inhibitors or inducers of CYP3A4 (erythromycin, ritonavir, telithromycin, rifampin), HMG-CoA Reductase Inhibitors (Simvastatin, Lovastatin, Atorvastatin), Beta Blockers (Timolol eyedrops, Metoprolol), Neuromuscular Blocking Agents (curare-like and depolarizing), Antihypertensive Agents (Prazosin and vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta blockers), Inhalation Anesthetics, Disopyramide, Flecainide, Quinidine, Cimetidine, Lithium, Carbamazepine, Phenobarbital, Cyclosporine, Digitalis, Aliskiren, Ramipril and Ramiprilat, aspirin.
- Fluent in English.
- Willing to take HB-1 or placebo.
- Willing and able to provide informed consent indicating an understanding of the requirements of the study and a willingness to comply with scheduled visits and all study procedures.
- Female patients must be surgically sterile (or have a monogamous partner who is surgically sterile) or be least 2 years postmenopausal or commits to use 2 acceptable forms of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 4 months following the last dose of study treatment. Male patients must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 4 months following the last dose of study treatment. Individuals who are involved exclusively in same-sex relationships are exempt from the birth control requirements but must agree to abide by the recommendations if they do engage in a heterosexual relationship.
- Female patients who are women of childbearing potential (WOCBP) must have a negative pregnancy test at Screening, within 7 days of dosing with study treatment.
Exclusion Criteria:
- Severe uncontrolled cardiac disease within 6 months of Screening, including but not limited to uncontrolled hypertension, hypotension (defined as below 90/60); unstable angina; myocardial infarction (MI) or cerebrovascular accident (CVA).
- Any clinically significant electrocardiogram (ECG) abnormalities at screening.
- Inadequate hepatic function defined as total bilirubin >1.5 × the upper limit of normal (ULN) ranges of each institution, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >3 × the ULN range of each institution.
- Inadequate renal function defined as serum creatinine >1.5 × the ULN range of each institution and/or eGFR <60.
- Any clinically significant abnormalities in clinical laboratory assessments as assessed by the Investigator.
- Any other systemic conditions or organ abnormalities that in the opinion of the Investigator may interfere with the conduct and/or interpretation of the current study.
- Unable to complete neuropsychological testing.
- Diagnosis of Bipolar I, Bipolar II disorder or Schizophrenia.
- History of suicidal behaviors including ideation.
- Current treatment with doses of benzodiazepines that are outside the FDA-approved prescriber's information.
- Already on treatment with either telmisartan or verapamil or both.
- Documented prior drug allergy to either telmisartan or verapamil.
- Documented contraindication to taking telmisartan or verapamil: (eg, Duchenne's muscular dystrophy, myasthenia gravis).
- Documented moderate to severe substance abuse within the last 6 months (recreational cannabis use is allowed).
- Pregnant or breastfeeding.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active Treatment (HB-01)
Approximately 40 patients will receive HB-01 active study drug.
|
HB-1 will be supplied as a dual active pharmaceutical ingredient tablet.
Other Names:
|
Placebo Comparator: Placebo Treatment
Approximately 40 patients will receive a matched placebo.
|
HB-1 matched placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events
Time Frame: Baseline, Week 2, Week 4, Week 8 and Week 12
|
Safety will be evaluated through Adverse Event monitoring, review of clinically significant changes in routine laboratory tests, ECGs, and orthostatic vital signs.
|
Baseline, Week 2, Week 4, Week 8 and Week 12
|
Number of Panic Attacks
Time Frame: Baseline, Week 2, Week 4, Week 8 and Week 12
|
Efficacy will be evaluated through a comparison of the number of panic attacks from Baseline as compared to protocol-specified timepoints per protocol.
|
Baseline, Week 2, Week 4, Week 8 and Week 12
|
Change in Panic Disorder Symptom Severity Scale (PDSS)
Time Frame: Baseline, Week 2, Week 4, Week 8 and Week 12
|
Efficacy will be evaluated through an evaluation in PDSS scores from Baseline as compared to protocol-specified timepoints per protocol.
|
Baseline, Week 2, Week 4, Week 8 and Week 12
|
Change in Clinical Global Impression-Severity Scale (CGI-I)
Time Frame: Baseline, Week 2, Week 4, Week 8 and Week 12
|
Efficacy will be evaluated through an evaluation in CGI-I scores from Baseline as compared to protocol-specified timepoints per protocol.
|
Baseline, Week 2, Week 4, Week 8 and Week 12
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David Walling, Collaborative NeuroScience Research, Garden Grove, CA
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HB-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Panic Disorder
-
Philipps University Marburg Medical CenterGerman Federal Ministry of Education and ResearchCompletedPanic Disorder With Agoraphobia | Panic Disorder Without AgoraphobiaGermany
-
Ulrike WillutzkiUnknownDepression | Panic Disorder | Agoraphobia | Panic Disorder With Agoraphobia | Agoraphobia With Panic AttacksGermany
-
Beth Israel Medical CenterTerminatedPanic Disorder | Major Depressive Disorder With Panic AttacksUnited States
-
Charite University, Berlin, GermanyRecruitingGeneralized Anxiety Disorder | Social Anxiety Disorder | Panic Disorder With Agoraphobia | Panic Disorder Without AgoraphobiaGermany
-
Southern Methodist UniversityBoston University; University of MichiganCompletedPanic Disorder With AgoraphobiaUnited States
-
Karolinska InstitutetCompleted
-
Region SkaneCompletedPanic Disorder (With or Without Agoraphobia)Sweden
-
Michael E. DeBakey VA Medical CenterSouth Central VA Mental Illness Research, Education & Clinical CenterUnknown
-
Beth Israel Medical CenterCompletedPanic Disorder | Major Depression With Panic AttacksUnited States
-
Ruhr University of BochumTerminatedPanic Disorder With AgoraphobiaGermany
Clinical Trials on HB-01
-
Johnson & Johnson Pte LtdShanghai China-Norm Management Consulting co.,LTD; Shanghai Skin Disease HospitalCompleted
-
Hookipa Biotech GmbHRecruitingHPV-Related Squamous Cell CarcinomaUnited States, Spain, Netherlands
-
Hope BiosciencesThe University of Texas Health Science Center, HoustonActive, not recruiting
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesNo longer availableParkinson DiseaseUnited States
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesNo longer availablePost COVID-19 SyndromeUnited States
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesNo longer availableAmyotrophic Lateral SclerosisUnited States
-
Hope Biosciences Stem Cell Research FoundationNo longer available
-
Hope BiosciencesThe University of Texas Health Science Center, HoustonNo longer availableSpinal Cord Injury at C5-C7 LevelUnited States
-
Hookipa Biotech GmbHCentre for Vaccinology Ghent - CEVACCompletedCytomegalovirus InfectionBelgium
-
Hope Biosciences Stem Cell Research FoundationHope BiosciencesNo longer availableSystem; Lupus ErythematosusUnited States